Comparative Pharmacology
Head-to-head clinical analysis: ANSOLYSEN versus APRESOLINE ESIDRIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANSOLYSEN versus APRESOLINE ESIDRIX.
ANSOLYSEN vs APRESOLINE-ESIDRIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pentolinium (ANSOLYSEN) is a ganglionic blocking agent that competitively antagonizes nicotinic acetylcholine receptors at autonomic ganglia, blocking both sympathetic and parasympathetic transmission.
Apresoline (hydralazine) is a direct-acting vasodilator that relaxes arteriolar smooth muscle via unknown mechanism; Esidrix (hydrochlorothiazide) is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule.
Initial: 2.5 mg intramuscularly or subcutaneously every 6 hours, gradually increased to 5-20 mg every 6 hours as needed.
Hydralazine (Apresoline): Oral, initial 10 mg 4 times daily for first 2-4 days, then increase to 25 mg 4 times daily for first week, then 50 mg 4 times daily thereafter. Maximum daily dose: 300 mg. Hydrochlorothiazide (Esidrix): Oral, initial 12.5-25 mg once daily, may increase to 50 mg once daily if needed.
None Documented
None Documented
Terminal elimination half-life is 6-8 hours in patients with normal renal function; may be prolonged to 24-48 hours in renal impairment, necessitating dose adjustment.
Hydralazine: 2-8 h (prolonged in renal impairment); Hydrochlorothiazide: 6-15 h (mean 10 h, increased in renal failure).
Renal excretion predominates (approximately 70-80% as unchanged drug via glomerular filtration; remainder as metabolites). Biliary/fecal elimination accounts for <10%.
Renal: Hydralazine 85-90% as metabolites, 5-10% unchanged; Hydrochlorothiazide 95% as unchanged drug. Biliary/fecal: Hydralazine <10%.
Category C
Category C
Antihypertensive
Antihypertensive